Literature DB >> 25005242

Excellent outcome of young adults with aggressive non-Hodgkin lymphomas treated with CHOP-like regimens.

K Hohloch1, S Zeynalova2, G Held3, M Ziepert2, M Loeffler2, G Wulf1, N Schmitz4, M Pfreundschuh3, L Trümper1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 25005242     DOI： 10.1038/leu.2014.213

Source DB:  PubMed          Journal:  Leukemia        ISSN： 0887-6924            Impact factor:   11.528


× No keyword cloud information.
  12 in total

1.  Non-Hodgkin's lymphoma in adolescents: experiences in 378 adolescent NHL patients treated according to pediatric NHL-BFM protocols.

Authors:  B Burkhardt; I Oschlies; W Klapper; M Zimmermann; W Woessmann; A Meinhardt; E Landmann; A Attarbaschi; F Niggli; M Schrappe; A Reiter
Journal:  Leukemia       Date:  2010-10-29       Impact factor: 11.528

2.  Dose-escalated CHOEP for the treatment of young patients with aggressive non-Hodgkin's lymphoma: II. Results of the randomized high-CHOEP trial of the German High-Grade Non-Hodgkin's Lymphoma Study Group (DSHNHL).

Authors:  M Pfreundschuh; C Zwick; S Zeynalova; U Dührsen; K-H Pflüger; T Vrieling; R Mesters; H-G Mergenthaler; H Einsele; M Bentz; E Lengfelder; L Trümper; C Rübe; N Schmitz; M Loeffler
Journal:  Ann Oncol       Date:  2007-12-06       Impact factor: 32.976

3.  High-dose therapy followed by autologous stem-cell transplantation with and without rituximab for primary treatment of high-risk diffuse large B-cell lymphoma.

Authors:  B Glass; M Ziepert; M Reiser; M Freund; L Trümper; B Metzner; A Feller; M Loeffler; M Pfreundschuh; N Schmitz
Journal:  Ann Oncol       Date:  2010-05-05       Impact factor: 32.976

4.  Conventional chemotherapy (CHOEP-14) with rituximab or high-dose chemotherapy (MegaCHOEP) with rituximab for young, high-risk patients with aggressive B-cell lymphoma: an open-label, randomised, phase 3 trial (DSHNHL 2002-1).

Authors:  Norbert Schmitz; Maike Nickelsen; Marita Ziepert; Mathias Haenel; Peter Borchmann; Christian Schmidt; Andreas Viardot; Martin Bentz; Norma Peter; Gerhard Ehninger; Gottfried Doelken; Christian Ruebe; Lorenz Truemper; Andreas Rosenwald; Michael Pfreundschuh; Markus Loeffler; Bertram Glass
Journal:  Lancet Oncol       Date:  2012-11-16       Impact factor: 41.316

5.  A biologic definition of Burkitt's lymphoma from transcriptional and genomic profiling.

Authors:  Michael Hummel; Stefan Bentink; Hilmar Berger; Wolfram Klapper; Swen Wessendorf; Thomas F E Barth; Heinz-Wolfram Bernd; Sergio B Cogliatti; Judith Dierlamm; Alfred C Feller; Martin-Leo Hansmann; Eugenia Haralambieva; Lana Harder; Dirk Hasenclever; Michael Kühn; Dido Lenze; Peter Lichter; Jose Ignacio Martin-Subero; Peter Möller; Hans-Konrad Müller-Hermelink; German Ott; Reza M Parwaresch; Christiane Pott; Andreas Rosenwald; Maciej Rosolowski; Carsten Schwaenen; Benjamin Stürzenhofecker; Monika Szczepanowski; Heiko Trautmann; Hans-Heinrich Wacker; Rainer Spang; Markus Loeffler; Lorenz Trümper; Harald Stein; Reiner Siebert
Journal:  N Engl J Med       Date:  2006-06-08       Impact factor: 91.245

6.  Dose-escalated CHOP plus etoposide (MegaCHOEP) followed by repeated stem cell transplantation for primary treatment of aggressive high-risk non-Hodgkin lymphoma.

Authors:  Bertram Glass; Marita Kloess; Martin Bentz; Günter Schlimok; Wolfgang E Berdel; Alfred Feller; Lorenz Trümper; Markus Loeffler; Michael Pfreundschuh; Norbert Schmitz
Journal:  Blood       Date:  2005-12-29       Impact factor: 22.113

Review 7.  Malignant hematologic diseases in adolescents and young adults.

Authors:  William A Wood; Stephanie J Lee
Journal:  Blood       Date:  2011-03-11       Impact factor: 22.113

8.  Dose-escalated CHOEP for the treatment of young patients with aggressive non-Hodgkin's lymphoma: I. A randomized dose escalation and feasibility study with bi- and tri-weekly regimens.

Authors:  L Trümper; C Zwick; M Ziepert; K Hohloch; R Schmits; M Mohren; R Liersch; M Bentz; U Graeven; U Wruck; M Hoffmann; B Metzner; D Hasenclever; M Loeffler; M Pfreundschuh
Journal:  Ann Oncol       Date:  2008-01-22       Impact factor: 32.976

9.  Molecular profiling of pediatric mature B-cell lymphoma treated in population-based prospective clinical trials.

Authors:  Wolfram Klapper; Monika Szczepanowski; Birgit Burkhardt; Hilmar Berger; Maciej Rosolowski; Stefan Bentink; Carsten Schwaenen; Swen Wessendorf; Rainer Spang; Peter Möller; Martin Leo Hansmann; Heinz-Wolfram Bernd; German Ott; Michael Hummel; Harald Stein; Markus Loeffler; Lorenz Trümper; Martin Zimmermann; Alfred Reiter; Reiner Siebert
Journal:  Blood       Date:  2008-05-28       Impact factor: 22.113

10.  Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of young patients with good-prognosis (normal LDH) aggressive lymphomas: results of the NHL-B1 trial of the DSHNHL.

Authors:  Michael Pfreundschuh; Lorenz Trümper; Marita Kloess; Rudolf Schmits; Alfred C Feller; Christian Rudolph; Marcel Reiser; Dieter K Hossfeld; Bernd Metzner; Dirk Hasenclever; Norbert Schmitz; Bertram Glass; Christian Rübe; Markus Loeffler
Journal:  Blood       Date:  2004-02-24       Impact factor: 22.113
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.